Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

August 13, 2026 - 05:42

Belite Bio has announced its unaudited financial results for the second quarter of 2026, alongside a corporate update highlighting significant regulatory milestones. The company confirmed that the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, a treatment for Stargardt disease type 1, with Priority Review designation. The agency has set a Prescription Drug User Fee Act target action date of February 12, 2027.

In addition to the regulatory progress, Belite Bio presented new secondary endpoint data from the Phase 3 DRAGON trial at the American Society of Retina Specialists Annual Meeting. The findings showed that quantitative autofluorescence, a key imaging biomarker, demonstrated a marked divergence between treatment groups, further supporting the therapeutic benefit of tinlarebant in slowing disease progression.

The company continues to advance its clinical pipeline and remains focused on bringing this potential therapy to patients with limited treatment options. Financial details from the quarter were disclosed in the full report, reflecting ongoing investment in research and development activities.